March 9, 2023

Low-dose IL-2 treatment may provide a new option for patients with chronic spontaneous urticaria who do not respond to traditional therapies. Chronic spontaneous urticaria (CSU) can significantly impact patients’ quality of life, and a substantial proportion remains unresponsive to traditional therapies. While second-generation H1-antihistamines are the first-line treatment, they may only be effective for some...